1. Clinical & Scientific Overview
Azathioprine & Mycophenolate Mofetil (MMF) (TIP-MED-000126, Reference Code [7.24]) is classified under
Pain, Inflammation, Rheumatology & Gout Medicines (Ch 07) as a Purine Antimetabolite Immunosuppressants (Schedule H | NLEM 2022 | HIGH-ALERT).
Within the Indian regulatory and compendial framework, it is governed under Schedule H & Schedule G Prescription Drug ('Caution: It is dangerous to take this preparation except under medical supervision' — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 07 [7.24], p. 90): Azathioprine: Azoran (RPG Life Sciences), Imuran. Mycophenolate Mofetil: CellCept (Roche), Mycept (Panacea), Mofilet (Emcure); Enteric-Coated Mycophenolate Sodium: Myfortic (Novartis), Renodapt-S (180 mg / 360 mg) — Strengths & Dosage Forms: Azathioprine Tablets: 25 mg, 50 mg. MMF Capsules/Tablets: 250 mg, 500 mg (MMF 500 mg = Myfortic 360 mg EC — NOT mg-for-mg interchangeable!)
Azathioprine Tablets: 25 mg, 50 mg. MMF Capsules/Tablets: 250 mg, 500 mg (MMF 500 mg = Myfortic 360 mg EC — NOT mg-for-mg interchangeable!)
3. Mechanism of Action & Pharmacodynamics
Purine Antimetabolite Immunosuppressants (Schedule H | NLEM 2022 | HIGH-ALERT) acting on target receptor/enzyme pathways in Pain, Inflammation, Rheumatology & Gout Medicines (Ch 07): clinical efficacy is mediated via Purine Antimetabolite Immunosuppressants (Schedule H | NLEM 2022 | HIGH-ALERT) for Renal, hepatic, and cardiac transplant rejection prophylaxis; lupus nephritis, severe SLE, autoimmune hepatitis, inflammatory bowel disease (Crohn's/UC), pemphigus vulgaris, and myasthenia gravis.
4. Therapeutic Indications & Evidence-Supported Uses
- Renal, hepatic, and cardiac transplant rejection prophylaxis
- lupus nephritis, severe SLE, autoimmune hepatitis, inflammatory bowel disease (Crohn's/UC), pemphigus vulgaris, and myasthenia gravis
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Azathioprine: 1–2.5 mg/kg/day PO OD or BD (Check TPMT/NUDT15 status!). MMF: 500–1000 mg PO BD (or Myfortic 360–720 mg BD)
Administration & Meal Timing: Take Azathioprine WITH food to reduce nausea; take MMF on an empty stomach (swallow capsules/tablets whole — never open or crush MMF/Myfortic due to teratogenic powder exposure!) | Morning & Evening (12-hourly BD) or OD with food (Azathioprine)
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: Reduce Azathioprine dose in CKD Stage 4–5; cap MMF at max 1000 mg BD if eGFR <25 mL/min. Hepatic: Monitor LFTs closely on Azathioprine
Renal: Reduce Azathioprine dose in CKD Stage 4–5; cap MMF at max 1000 mg BD if eGFR <25 mL/min. Hepatic: Monitor LFTs closely on Azathioprine
Renal: Reduce Azathioprine dose in CKD Stage 4–5; cap MMF at max 1000 mg BD if eGFR <25 mL/min. Hepatic: Monitor LFTs closely on Azathioprine
7. Contraindications, Precautions & High-Risk Warnings
- HIGH-ALERT LASA & TERATOGENICITY WARNINGS: (1) LASA: Azoran (Azathioprine) vs. Zyloric (Allopurinol) / Azithral (Azithromycin)! (2) MMF is a POTENT HUMAN TERATOGEN (strictly contraindicated in pregnancy; switch to Azathioprine >=6 weeks before conception in SLE/transplant women!). (3) TPMT or NUDT15 genetic deficiency (NUDT15 variants occur in ~10–15% of Indian patients!) causes rapid fatal pancytopenia on standard Azathioprine doses!
Key Clinical Precautions: Renal: Reduce Azathioprine dose in CKD Stage 4–5; cap MMF at max 1000 mg BD if eGFR <25 mL/min. Hepatic: Monitor LFTs closely on Azathioprine
8. Adverse Effects Profile
- Nausea, diarrhoea (very common with MMF — Myfortic EC improves GI tolerance), leukopenia, mild hepatotoxicity
- Severe bone-marrow suppression (leukopenia, thrombocytopenia, fatal pancytopenia), hepatotoxicity, acute pancreatitis (Azathioprine), opportunistic infections, lymphoma/skin malignancy risk
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- CRITICAL ALLOPURINOL / FEBUXOSTAT + AZATHIOPRINE INTERACTION: Allopurinol and Febuxostat block xanthine oxidase breakdown of 6-MP, increasing active thioguanine nucleotides 3–4-fold and causing FATAL PANCYTOPENIA! Avoid combination unless explicitly directed by a specialist with a 65%–75% Azathioprine dose reduction and weekly CBCs! 5-ASA and Co-trimoxazole also increase myelosuppression
- Antacids, Iron, Calcium, and PPIs reduce MMF absorption
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: COUNTER CHECK: Verify 'Azoran' vs 'Zyloric' and confirm the patient is NOT taking Allopurinol or Febuxostat! Weekly blood counts (CBC) during the first 2 months are mandatory; report fever, sore throat, mouth ulcers, or bruising immediately; women on CellCept/Mycept must use dual contraception
- Meal & Clock Timing Instruction: Take Azathioprine WITH food to reduce nausea; take MMF on an empty stomach (swallow capsules/tablets whole — never open or crush MMF/Myfortic due to teratogenic powder exposure!) (Morning & Evening (12-hourly BD) or OD with food (Azathioprine))
- Missed Dose Protocol: Take as soon as remembered; never miss transplant doses or double a dose
- Geriatric Dispensing Pearl: Higher myelosuppression and infection risk in older adults; monitor CBC and renal function closely
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Azathioprine Tablets: 25 mg, 50 mg. MMF Capsules/Tablets: 250 mg, 500 mg (MMF 500 mg = Myfortic 360 mg EC — NOT mg-for-mg interchangeable!)
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 07 [7.24] (p. 90)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [7.26] Baclofen & Tizanidine Hydrochloride — GABA-B Receptor Agonist & Central Alpha-2 Adrenoceptor Agonist An
- [7.13]-C44 Tolperisone Hydrochloride — Centrally Acting Skeletal Muscle Relaxants & Antispasticity Agent
- [7.13]-C45 Chlorzoxazone — Centrally Acting Skeletal Muscle Relaxants & Antispasticity Agent
- [7.14]-C46 Meloxicam — Long-Half-Life Oxicam NSAIDs — Non-Selective & Preferential COX-2
